Finance entity
Weiss Ratings is the most frequent co-covered peer, appearing in 7 of the 12 tracked stories. The clearest coverage concentration is markets: 8 of 12 stories, with the rest divided among 1 other category. Sentiment skews less negative than the wider beat, at 0% negative against 22% across all 1216 Finance stories in the same window.
Last mentioned: 23h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 8 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 7 of the 12 tracked stories. The clearest coverage concentration is markets: 8 of 12 stories, with the rest divided among 1 other category. Sentiment skews less negative than the wider beat, at 0% negative against 22% across all 1216 Finance stories in the same window. That works out to roughly 1.3 stories per week across a 63-day span. The busiest single day carried 2. Their average consequence score of 5.1 runs below the beat's 5.8 for that window. Each story carries 2.1 original sources on average, compared with 2.6 for the broader beat in this window. This profile follows 12 Finance stories mentioning Piper Sandler across the period from July 9, 2026 to September 9, 2026.
Computed from the 12 stories linked to this entity, with beat comparisons drawn from all 1216 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Piper Sandler. Shared-story counts are live from our verified record — not editorial picks.
Insider Filings Publicized; Shares Fall 3%
Form 4 filing disclosed; MRCY shares trade down $2.87 midday to $91.36 on 1.12M shares vs average 675,344.
Farnsworth Sells $645,794.04 in MRCY Stock
EVP David Farnsworth sells 6,612 shares at average $97.67, reducing direct ownership by 5.31% to 117,967 shares.
MRCY Reports Mixed Q4; Ratner Sells Shares
Mercury Systems posts EPS of $0.37 vs $0.38 consensus and revenue of $289.78M vs $266.09M. EVP Steven Ratner sells 1,971 shares at $111.36 for $219,490.56 to cover tax withholding.
Quarterly earnings released
SMBC reports EPS of $1.83 vs. $1.52 estimate, revenue of $51.77M.
Wells Fargo Cuts Target to $70
Wells Fargo & Company lowers Freshpet’s price target from $75.00 to $70.00, keeping an Overweight rating, implying 28.42% upside.
Bank of America Lowers Target
Bank of America reduces its price target from $75.00 to $70.00 and maintains a Neutral rating.
Piper Sandler adjusts PT
Piper Sandler reiterates Neutral, boosts target from $71 to $79.
Piper Sandler Stays Overweight
Piper Sandler reaffirms an Overweight rating on Freshpet shares.
Insider sale by EVP Windes
EVP Richard Windes sells 2,000 shares at average $69.70, totaling $139,400.
Weiss Ratings reiterates Buy
Weiss Ratings issues a 'buy (b)' rating on SMBC.
Weiss Ratings Downgrades
Weiss Ratings cuts Freshpet from 'Hold (c)' to 'Hold (c-)'.
JPMorgan Upgrades, Others Reaffirm
JPMorgan raises rating from Neutral to Overweight and lifts target from $66.00 to $68.00. Morgan Stanley reiterates Overweight with $77.00 target, while Deutsche Bank holds at Hold with $63.00 target.
Stephens bullish call
Stephens reiterates Overweight rating, lifts PT to $76 from $72.
Jefferies Cuts Target
Jefferies Financial Group lowers its price objective from $75.00 to $70.00 and maintains a Hold rating.
KBW target price increase
Keefe, Bruyette & Woods raises price target from $64 to $65, maintaining Market Perform rating.
TD Cowen Turns Bullish
TD Cowen upgrades Freshpet from Hold to Buy and sets an $80.00 price objective.
Oppenheimer Upgrades Freshpet
Oppenheimer raises Freshpet from Market Perform to Outperform with an $80.00 price target.
A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Tuesday's midday tape lifted MARA 4.6% to $11.83 and Sterling Infrastructure 3.2% to $502.20, but the more important signal for investors is a multi-week pattern of analyst price-target cuts. MARA's consensus target of $18.78 implies large upside yet carries 5.32 beta and negative earnings; STRL's $690.33 target still sits 37% above its price but below prior $900-plus targets. Finance readers should weigh consensus 'Moderate Buy' labels against balance-sheet and technical risks.
Source: themarketsdaily.com · tickerreport.com
Hollencrest Capital Management nearly exited UNH in Q2 2026, but much larger institutions piled in. Analysts remain bullish with price targets up to $490. For finance readers, the 13F reveals a rotation in shares rather than a fundamental warning.
Source: Ticker Report · Daily Political
Two Mercury Systems EVPs disclosed sell-to-cover trades totaling about $865K after an EPS miss of $0.01 and revenue beat. The transactions were driven by tax withholding on vested awards, but the stock's slide below moving averages adds pressure. Investors should separate mechanical insider flows from fundamental margin challenges.
Source: MarketBeat · themarketsdaily.com
Institutional 13F data shows new accumulation in Chubb as small advisory firms added positions from Q4 2025 through Q2 2026. Analyst targets range from $301 to $386, while insider sales and 83.81% institutional ownership frame a mixed but liquid market for CB.
Source: Ticker Report · Daily Political
Wells Fargo lowered Check Point's target to $130, highlighting a divided analyst community with an average target of $149.48. The stock's depressed valuation and low beta present a potential value opportunity against high-growth cyber peers.
Source: dailypolitical.com · themarketsdaily.com
Benchmark boosted outlooks on two disparate stocks—First Internet Bancorp and DexCom—offering a stark contrast in risk/reward. While INBK promises 21.74% upside based on the new $35 target, DXCM’s $82 target sits slightly below its trading price, highlighting valuation concerns despite a Buy rating.
Source: dailypolitical.com · themarketsdaily.com
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Southern Missouri Bancorp delivered a strong quarter with earnings of $1.83 per share, beating estimates by $0.31 on revenue of $51.77 million. However, the stock fell 1.4% to $75.41 as analysts remain divided and insider selling raises questions.
Source: MarketBeat · tickerreport.com
WaFd (WAFD) reported quarterly EPS of $0.81, missing consensus by 2.4%, while the stock trades near a 52-week high and offers a 2.7% dividend yield. Analysts are split between hold and buy, and an insider sale adds caution. For income-focused investors, the small miss may be overshadowed by the stable payout and institutional accumulation.
Source: MarketBeat · themarketsdaily.com
Despite a 34% cut to adjusted EBITDA estimates, Coinbase stock rallied on an Outperform rating from William Blair, signaling that the worst may be priced in. The firm expects a 44% drop in 2026 trading volumes before a rebound, while Piper Sandler lowered its target but remained neutral.
Source: finance.yahoo.com · Decrypt
Wells Fargo lowered its price target on Freshpet to $70 from $75 while maintaining an Overweight rating, implying the stock is undervalued by 28%. The market remains skeptical with FRPT trading at $54.51, well below the consensus analyst target of $74.25. Analysts overall rate the pet food company a Moderate Buy, despite a string of recent target cuts.
Source: Watch List News · Ticker Report
Piper Sandler is linked from 12 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
